Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.

08:00 EDT 9th July 2019 | BioPortfolio

Summary of "Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection."

Plazomicin, an aminoglycoside, overcomes aminoglycoside modifying enzymes with in vitro potency against multidrug resistant Enterobacteriales. The exposure response relationship of plazomicin and comparator aminoglycoside amikacin was determined for Escherichia coli while for Klebsiella pneumoniae only plazomicin was tested. An in vitro pharmacokinetic (PK) model was used. Five strains of E.coli (2 meropenem resistant) and 5 strains of K.pneumoniae (2 meropenem resistant) plazomicin MICs 0.5-4mg/L were used. Antibacterial effect was assessed by changes in bacterial load and changes in bacterial population profile. The correlation between change in initial inoculum after 24h drug exposure and area under the concentration curve to MIC ratio (AUC/MIC) was good (plazomicin R ≥0.8302, amikacin R ≥0.9520). E.coli plazomicin AUC/MIC ratios for 24h static, -1 log drop, -2 log drop and -3 log drop were 36.1±18.4, 39.3±20.9, 41.2±21.9 and 44.8±24.4 respectively, and for amikacin were 49.5±12.7, 55.7±14.8, 64.1±19.2 and 73.3±25.3. K.pneumoniae plazomicin AUC/MIC ratios for 24h static, -1 log drop, -2 log drop and -3 log drop were 34.0±15.2, 46.8±27.8, 67.4±46.5 and 144.3±129.8. Plazomicin AUC/MIC ratios >66, and amikacin AUC/MIC ratios >57.7, were associated with suppression of E.coli growth on MICx4 or x8 recovery plates. The equivalent plazomicin AUC/MIC to suppress emergence of resistance with K.pneumoniae was >132. The plazomicin AUC/MIC for 24h static effect and -1 log reduction in E.coli and K.pneumoniae bacterial load was in the range 30-60. Plazomicin AUC/MIC targets aligned with those of amikacin for E.coli.


Journal Details

This article was published in the following journal.

Name: International journal of antimicrobial agents
ISSN: 1872-7913


DeepDyve research library

PubMed Articles [10656 Associated PubMed Articles listed on BioPortfolio]

Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin.

The emergence of multi-drug resistant (MDR) Gram-negative pathogens has become a serious worldwide health concern. Gram-negative bacteria such as Enterobacteriaceae (Klebsiella pneumoniae, Escherichia...

No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.

Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae. Because plazomici...

A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics.

Plazomicin is an aminoglycoside with in vitro activity against multidrug-resistant Enterobacteriaceae. A phase 1, randomized, double-blind, crossover study assessed the potential effects of plazomicin...

Once-Daily Plazomicin for Complicated Urinary Tract Infections.

The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-re...

Optimization and Designing of Amikacin-loaded Poly D, L-Lactide-co-glycolide Nanoparticles for Effective and Sustained Drug Delivery.

Amikacin, a water-soluble aminoglycoside antibiotic used to treat gram-negative bacillary infections, is a Biopharmaceutics Classification System class III drug having poor permeability and short half...

Clinical Trials [6972 Associated Clinical Trials listed on BioPortfolio]

An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey

This is an international observational cohort study on current aminoglycoside practices in intensive care units. Clinical and demographic data, dosing and therapeutic drug monitoring data ...

Dosage Piperacillin/Tazobactam and Amikacin in ICU

The pharmacokinetics of antimicrobials is profoundly modified in Intensive care unit (ICU) patients. To adapt the treatment, it is recommended to measure blood levels of antibiotics. Some ...

A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin

This is a single-center, Phase 1, open label, randomized, two-sequence, two-period, crossover study to evaluate the drug-drug interaction potential between plazomicin and metformin in heal...

A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

This is a Phase 3, randomized, open-label superiority study comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecy...

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

This is a single-center, open label, non-randomized metabolism, excretion, and mass balance study of a single IV infusion of [14C]-plazomicin in healthy, adult male subjects.

Medical and Biotech [MESH] Definitions

A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.

An assisted reproductive technique that includes the direct handling and manipulation of oocytes and sperm to achieve fertilization in vitro.

A semi-synthetic aminoglycoside antibiotic that is used in the treatment of TUBERCULOSIS.

Naturally occurring genetic variations associated with drug response (e.g., dosage, extent and rate of metabolic processes). While these variants are not markers for GENETIC PREDISPOSITION TO DISEASE they influence PHARMACOKINETICS and pharmacodynamics and often occur on genes encoding drug metabolism enzymes and transporters (e.g., ANGIOTENSIN CONVERTING ENZYME; CYTOCHROME P-450 CYP2D6).

Quick Search


DeepDyve research library

Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Pneumonia (bronchopneumonia, lobar pneumonia and double pneumonia) is inflammation (swelling) of the tissue in one or both of your lungs. It is usually caused by an pneumococcal infection caused by bacteria called Streptococcus pneumoniae.  However,...

Searches Linking to this Article